Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: Implications for therapy of cutaneous T-cell lymphoma

American Journal of Hematology

Volumn 87, Issue 2, 2012, Pages 226-228

  Stephen, Sasha ^a   Morrissey, Kelly A ^a   Benoit, Bernice M ^a   Kim, Ellen J ^a   Vittorio, Carmela C ^a   Nasta, Sunita D ^b   Showe, Louise C ^b   Wysocka, Maria ^a   Rook, Alain H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; BEXAROTENE; CD56 ANTIGEN; GAMMA INTERFERON; PSORALEN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; VORINOSTAT;

AGED; ANTIGEN PRESENTING CELL; CANCER GROWTH; CANCER RELAPSE; CASE REPORT; CELLULAR IMMUNITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DOSE RESPONSE; ERYTHRODERMA; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION SENSITIVITY; LETTER; LYMPHADENOPATHY; MONOCYTE; NATURAL KILLER CELL; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUVA; RECURRENT CANCER; REMISSION; SEZARY SYNDROME; ULTRAVIOLET A RADIATION;

AGED; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; IMMUNITY, CELLULAR; IMMUNOMODULATION; K562 CELLS; KILLER CELLS, NATURAL; ROC CURVE; SEZARY SYNDROME;

EID: 84855956665     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22231     Document Type: Letter

References (12)

1. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 2007; 26: 5541-5552.
2. Zhang C, Richon V, Ni X, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. J Invest Dermatol 2005; 125: 1045-1052.
3. Glauben R, Batra A, Fedke I, et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 2006; 176: 5015-5022.
4. Reddy P, Maeda Y, Hotary K, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 2004; 101: 3921-3926.
5. Mishra N, Reilly CM, Brown DR, et al. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003; 111: 539-552.
6. Tao R, de Zoeten EF, Ozkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13: 1299-1307.
7. Gardner JM, Evans KG, Goldstein S, et al. Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma. Arch Dermatol 2009; 145: 985-988.
8. Leoni F, Fossati G, Lewis EC, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005; 11: 1-15.
9. Gerosa F, Baldani-Guerra B, Nisii C, et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002; 195: 327-333.
10. Rook AH, Kubin M, Cassin M, et al. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol 1995; 154: 1491-1498.
11. Wysocka M, Newton S, Benoit BM, et al. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: Synergy with interferon-γ enhances production of interleukin-12. Clin Lymphoma Myeloma 2007; 7: 524-534.
12. Ritchie D, Piekarz RL, Blombery P, et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: A case series report. Haematologica 2009; 94: 1618-1622.